Clinical trials
Ocular Hypertension trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
91 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 8 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Unknown status | 20 |
| Terminated | 9 |
| Withdrawn | 7 |
| Recruiting | 7 |
| Active, not recruiting | 3 |
| Suspended | 1 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| BelkinVision | 3 |
| Duke University | 3 |
| Sensimed AG | 3 |
| Temple University | 3 |
| Allergan | 2 |
| Aurolab | 2 |
| Benha University | 2 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 2 |
| Columbia University | 2 |
| Glaukos Corporation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ocular Hypertension | 91 |
| Glaucoma | 49 |
| Glaucoma, Open-Angle | 39 |
| Cataract | 7 |
| Diabetic Retinopathy | 5 |
| Eye Diseases | 5 |
| Exfoliation Syndrome | 4 |
| Macular Degeneration | 4 |
| Low Tension Glaucoma | 3 |
| Glaucoma, Angle-Closure | 2 |
Trials
Showing 1 to 25 of 91. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.